Zimbabwe’s national drug procurer NatPharm has assured Zimbabweans on second-line regimen antiretroviral (ARV) treatment that the currently low stocks of medication will soon be replenished.

The assurance came amid concerns among those who take second-line ARVs over the supply of drugs after the National AIDS Council last week said that stocks for the second-line regimen needed urgent replenishment, the Herald newspaper reported Monday.

NatPharm board chairperson Billy Rigava said work is in progress to avert a crisis.

“What we can tell the country is there is enough medication for those who are already on treatment and they should not panic as the medication will continue to be sourced,” he said. “The people who manufacture the drugs are known and there is a relationship that just has to be improved to make sure the medication is there.”

“Measures have been put in place to ensure we have the required medicines,” Rigava said.

About 1.4 million Zimbabweans are living with HIV and 88 percent are on treatment.

An HIV drug regimen has three lines: the first is taken by most patients, especially those who seek treatment early after infection; the second is more expensive and is given to people who are resistant to the first; and the third is the most expensive and has harsh side effects.

Disclaimer: News Ghana is not responsible for the reportage or opinions of contributors published on the website.

Send your news stories to [email protected] and via WhatsApp on +1-508-812-0505 

Previous articleCOVID-19 stalls issuing of birth certificates in Zimbabwe
Next articleCannavaro concerned about his team’s mental state
Xinhua News Agency, Xinhuanet is an important central news service-oriented website, an important information organ of the central government, and an important platform for building up China's online international communication capacity. Established on November 7, 1997, as an online news provider of the Xinhua News Agency, it was officially named Xinhuanet on March 10, 2000 and began around-the-clock news release with leading online public opinion at home and setting a good image of China abroad as its main task.


Please enter your comment!
Please enter your name here